权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Telemetric Microsensor for Glaucoma

青光眼遥测微传感器

基本信息

批准号：
8903820
负责人：
Kenneth Glen Goldman
金额：
$ 16.09万
依托单位：
H-CUBED, INC.
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-30 至 2017-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8903820
关键词：
Accounting Address Affect African American Air American Biocompatible Blindness Caliber Catheters Caucasians Characteristics Clinical Communication Contact Lenses Cornea Detection Devices Disease Management Electric Capacitance Elements Environment Eye Eyedrops Frequencies General Population Glaucoma Goals Gold Health Human Resources Implant Individual Lasers Latanoprost Length Measurement Measures Mechanics Medical Microfabrication Minimally Invasive Surgical Procedures Modality Monitor Nerve Pathogenesis Patient Education Patients Pharmaceutical Preparations Pharmacotherapy Phase Physicians&apos Offices Physiologic Intraocular Pressure Pressure Transducers Property Reader Reading Retinal Ganglion Cells Risk Factors Saline Sclera Self-Administered Signal Transduction Small Business Innovation Research Grant System Techniques Technology Telemetry Testing Thick Time Timolol Touch sensation Variant Visual Fields Width Wireless Technology anterior chamber base conjunctiva cost design effective therapy experience flexibility high intraocular pressure implanted sensor meetings microsensor modifiable risk new technology novel optic nerve disorder pressure public health relevance radiofrequency sensor standard measure success tonometry

项目摘要

DESCRIPTION (provided by applicant): Glaucoma is an optic nerve disease in which there is progressive loss of retinal ganglion cells leading to irreversible loss of vision. It is estimated o affect 2% of the general population. More than 2.3 million Americans are affected with glaucoma and it is estimated to account for nearly $3B in direct medical costs. It is estimated that 4% of Caucasian patients and 8% of African-American patients will experience blindness due to glaucoma. It is the second leading cause of blindness worldwide. High intraocular pressure (IOP) is the single largest, as well as the only modifiable, risk factor associated with glaucoma. Measuring and reducing IOP to levels that reduce the progression of visual field loss and nerve degradation is the current management approach for glaucoma. Typical treatment consists of IOP measurement in a clinical setting with a drug therapy of self-administered eye drops such as timolol and latanoprost. During periodic follow-ups, IOP and eye health is assessed and medication is adjusted as necessary until further progression is stopped or reduced. Reproducible and accurate IOP measurements are a critically important element of disease management. Goldman Applanation Tonometry (GAT) is the standard for measuring IOP. The most significant limitations of GAT are that it provides an indirect IOP measurement and only measures IOP at a single moment in time. However, even with these limitations, GAT has remained the gold standard for measuring IOP in the management of glaucoma. To overcome this, we propose the use of a micro-miniature, telemetric pressure sensor device for measuring IOP continuously and directly. As such, for the Phase I project we propose the following Specific Aims: (1) Demonstrate a low-profile micro pressure sensor with 0.5 mmHg accuracy; and (2) Establish microcoil designs on flexible substrates for wireless telemetric communication.